NCT00975637

Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 198 (actual)
• Sponsor: Bausch Health Americas, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12.

Detailed description

The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12. Subjects were randomized ina 1:1:1:1:1 ratio. Subjects randomized to receive AMG 827 received 70, 140, or 210 mg at day 1 and weeks 4 and 8.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	70 mg SC	70 mg SC
DRUG	210 mg SC	210 mg SC
DRUG	140 mg SC	140 mg SC
DRUG	280 mg SC	280 mg SC
DRUG	Placebo	Placebo SC

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-07-01
• Completion: 2010-09-01
• First posted: 2009-09-11
• Last updated: 2019-06-26
• Results posted: 2016-12-30